{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:31Z","timestamp":1791855811062,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T00:00:00Z","timestamp":1545091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00467-018-4172-3","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T11:27:14Z","timestamp":1545132434000},"page":"855-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome"],"prefix":"10.1007","volume":"34","author":[{"given":"Andrew P.","family":"Maxted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Dalrymple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Chisholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"McColl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yincent","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin T.","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben C.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,18]]},"reference":[{"issue":"9384","key":"4172_CR1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362(9384):629\u2013639","journal-title":"Lancet"},{"issue":"4","key":"4172_CR2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3109\/0886022X.2015.1010940","volume":"37","author":"SG \u00d6zl\u00fc","year":"2015","unstructured":"\u00d6zl\u00fc SG, Demircin G, T\u00f6kmeci N, \u00c7alt\u0131k Y\u0131lmaz A, Aydo\u011f \u00d6, B\u00fclb\u00fcl M, \u00d6ner A (2015) Long-term prognosis of idiopathic nephrotic syndrome in children. Ren Fail 37(4):672\u2013677","journal-title":"Ren Fail"},{"issue":"10","key":"4172_CR3","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00467-017-3780-7","volume":"33","author":"MJ Kemper","year":"2017","unstructured":"Kemper MJ, Valentin L, van Husen M (2017) Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatr Nephrol 33(10):1641\u20131649","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"4172_CR4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00467-016-3456-8","volume":"32","author":"AM Karp","year":"2016","unstructured":"Karp AM, Gbadegesin RA (2016) Genetics of childhood steroid-sensitive nephrotic syndrome. Pediatr Nephrol 32(9):1481\u20131488","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"4172_CR5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3345\/kjp.2015.58.8.275","volume":"58","author":"HG Kang","year":"2015","unstructured":"Kang HG, Cheong HI (2015) Nephrotic syndrome: what\u2019s new, what\u2019s hot? Korean J Pediatr 58(8):275\u2013282","journal-title":"Korean J Pediatr"},{"issue":"8\u20139","key":"4172_CR6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s004679900269","volume":"14","author":"EH Garin","year":"2000","unstructured":"Garin EH (2000) Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 14(8\u20139):872\u2013878","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"4172_CR7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00467-009-1226-6","volume":"24","author":"D Haffner","year":"2009","unstructured":"Haffner D, Fischer DC (2009) Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 24(8):1433\u20131438","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"4172_CR8","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/ndt\/gfi274","volume":"21","author":"MD Sinha","year":"2006","unstructured":"Sinha MD, MacLeod R, Rigby E, Clark AG (2006) Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 21(7):1848\u20131854","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"4172_CR9","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","volume":"95","author":"JD Hainsworth","year":"2000","unstructured":"Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD 3rd, Richards P, Greco FA (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95(10):3052\u20133056","journal-title":"Blood"},{"issue":"9","key":"4172_CR10","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793\u20132806","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4172_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","volume":"9","author":"HM G\u00fcrcan","year":"2009","unstructured":"G\u00fcrcan HM (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9(1):10\u201325","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"4172_CR12","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Gu\u00e9rin V, Lapillonne H, Desch\u00eanes G, Ulinski T (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood\u2013follow-up after CD19 recovery. Nephrol Dial Transplant 27(3):1083\u20131089","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"4172_CR13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84(5):1025\u20131033","journal-title":"Kidney Int"},{"issue":"9950","key":"4172_CR14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384(9950):1273\u20131281","journal-title":"Lancet"},{"key":"4172_CR15","unstructured":"Specialised commissioning Team, N.E. (2015) Clinical commissioning policy: rituximab for the treatment of relapsing steroid sensitive nephrotic syndrome. NHS England E03\/P\/b"},{"issue":"2","key":"4172_CR16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/br.2016.711","volume":"5","author":"XL Niu","year":"2016","unstructured":"Niu XL, Hao S, Wang P, Zhang W, Guo GM, Wu Y, Kuang XY, Zhu GH, Huang WY (2016) Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome. Biomed Rep 5(2):237\u2013242","journal-title":"Biomed Rep"},{"issue":"9","key":"4172_CR17","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl\u2019Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26(9):2259\u20132266","journal-title":"J Am Soc Nephrol"},{"key":"4172_CR18","doi-asserted-by":"publisher","unstructured":"Hogan J, Dossier C, Kwon T, Macher MA, Maisin A, Couderc A, Niel O, Baudouin V, Desch\u00eanes G (2018) Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. \n                    https:\/\/doi.org\/10.1007\/s00467-018-4052-x","DOI":"10.1007\/s00467-018-4052-x"},{"issue":"3","key":"4172_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00467-012-2310-x","volume":"28","author":"RM Lombel","year":"2013","unstructured":"Lombel RM, Gipson DS, Hodson EM, Kidney Disease: Improving Global Outcomes (2013) Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28(3):415\u2013426","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"4172_CR20","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19(7):794\u2013797","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4172_CR21","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6(6):1308\u20131315","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"4172_CR22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, Sako M, Iijima K (2013) Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 28(2):257\u2013264","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4172_CR23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, Macher MA, Loirat C, Gu\u00e9rin V, Watier H, Peuchmaur M, Baudouin V, Desch\u00eanes G (2010) Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 25(6):1109\u20131115","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"4172_CR24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00467-012-2406-3","volume":"28","author":"S Tellier","year":"2013","unstructured":"Tellier S, Brochard K, Garnier A, Bandin F, Llanas B, Guigonis V, Cailliez M, Pietrement C, Dunand O, Nathanson S, Bertholet-Thomas A, Ichay L, Decramer S (2013) Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol 28(6):911\u2013918","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"4172_CR25","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, D\u00f6tsch J (2012) Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 27(5):1910\u20131915","journal-title":"Nephrol Dial Transplant"},{"key":"4172_CR26","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1038\/srep08219","volume":"5","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Liao G, Li Y, Zhou S, Zou H (2015) The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis. Sci Rep 5:8219","journal-title":"Sci Rep"},{"issue":"1","key":"4172_CR27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13052-016-0271-6","volume":"42","author":"D Maratea","year":"2016","unstructured":"Maratea D, Bettio M, Corti MG, Montini G, Venturini F (2016) The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective. Ital J Pediatr 42(1):63","journal-title":"Ital J Pediatr"},{"issue":"4","key":"4172_CR28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","volume":"21","author":"S Fujinaga","year":"2017","unstructured":"Fujinaga S, Hirano D, Mizutani A, Sakuraya K, Yamada A, Sakurai S, Shimizu T (2017) Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment. Clin Exp Nephrol 21(4):671\u2013676","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"4172_CR29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","volume":"30","author":"A Sinha","year":"2015","unstructured":"Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, Bagga A (2015) Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 30(1):96\u2013106","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"4172_CR30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172(8):757\u2013764","journal-title":"JAMA Pediatr"},{"issue":"10","key":"4172_CR31","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/nep.12744","volume":"21","author":"E Papakrivopoulou","year":"2016","unstructured":"Papakrivopoulou E, Shendi AM, Salama AD, Khosravi M, Connolly JO, Trompeter R (2016) Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease. Nephrology (Carlton) 21(10):893\u2013900","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"4172_CR32","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00467-017-3746-9","volume":"33","author":"K Iijima","year":"2018","unstructured":"Iijima K, Sako M, Kamei K, Nozu K (2018) Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol 33(9):1449\u20131455","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4172-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4172-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4172-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T09:25:31Z","timestamp":1585905931000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4172-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,18]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4172"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4172-3","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,18]]},"assertion":[{"value":"2 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ben Reynolds has previously had speaking fees from Alexion Pharmaceuticals. The remaining authors have no financial relationships relevant to this article to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}